FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Richard Hazen

Research Profile

Chemicals & Drugs

Living Beings

HIV-1
HIV

Physiology

Concepts & Ideas

Co-author Network

Publications

TOP 3
Masanori Kobayashi; Tomokazu Yoshinaga; Takahiro Seki; Chiaki Wakasa-Morimoto; Kevin W Brown; Robert Ferris; Scott A Foster; Richard J Hazen; Shigeru Miki; Akemi Suyama-Kagitani; Shinobu Kawauchi-Miki; Teruhiko Taishi; Takashi Kawasuji; Brian A Johns; Mark Richard Underwood; Edward P Garvey; Akihiko Sato; Tamio Fujiwara
In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
Jingshan Ren; Philip P Chamberlain; Anna Stamp; Steven A Short; Kurt L Weaver; Karen R Romines; Richard J Hazen; Andrew Freeman; Robert G Ferris; C Webster Andrews; Lawrence Boone; Joseph H Chan; David K Stammers
Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
Edward P Garvey; Brian A Johns; Margaret J Gartland; Scott A Foster; Wayne H Miller; Robert G Ferris; Richard J Hazen; Mark Richard Underwood; Eric E Boros; James B Thompson; Jason G Weatherhead; Cecilia S Koble; Scott H Allen; Lee T Schaller; Ronald G Sherrill; Tomokazu Yoshinaga; Masanori Kobayashi; Chiaki Wakasa-Morimoto; Shigeru Miki; Koichiro Nakahara; Takeshi Noshi; Akihiko Sato; Tamio Fujiwara
The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Richard Hazen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Masanori Kobayashi; Tomokazu Yoshinaga; Takahiro Seki; Chiaki Wakasa-Morimoto; Kevin W Brown; Robert Ferris; Scott A Foster; Richard J Hazen; Shigeru Miki; Akemi Suyama-Kagitani; Shinobu Kawauchi-Miki; Teruhiko Taishi; Takashi Kawasuji; Brian A Johns; Mark Richard Underwood; Edward P Garvey; Akihiko Sato; Tamio Fujiwara
In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.
Antimicrobial agents and chemotherapy 2011;55(2):813-21.
2008: Jingshan Ren; Philip P Chamberlain; Anna Stamp; Steven A Short; Kurt L Weaver; Karen R Romines; Richard J Hazen; Andrew Freeman; Robert G Ferris; C Webster Andrews; Lawrence Boone; Joseph H Chan; David K Stammers
Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
Journal of medicinal chemistry 2008;51(16):5000-8.
2008: Edward P Garvey; Brian A Johns; Margaret J Gartland; Scott A Foster; Wayne H Miller; Robert G Ferris; Richard J Hazen; Mark Richard Underwood; Eric E Boros; James B Thompson; Jason G Weatherhead; Cecilia S Koble; Scott H Allen; Lee T Schaller; Ronald G Sherrill; Tomokazu Yoshinaga; Masanori Kobayashi; Chiaki Wakasa-Morimoto; Shigeru Miki; Koichiro Nakahara; Takeshi Noshi; Akihiko Sato; Tamio Fujiwara
The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.
Antimicrobial agents and chemotherapy 2008;52(3):901-8.
2007: Richard J Hazen; Robert Harvey; Robert G Ferris; Charles Craig; Phillip Yates; Philip Griffin; John Miller; Istvan Kaldor; John Ray; Vicente Samano; Eric S Furfine; Andrew Spaltenstein; Michael Hale; Roger D Tung; Marty St Clair; Mary H Hanlon; Lawrence R Boone
In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.
Antimicrobial agents and chemotherapy 2007;51(9):3147-54.
2006: Christopher McGuigan; Alshaimaa Hassan-Abdallah; Sheila Srinivasan; Yikang Wang; Adam Siddiqui; Susan M Daluge; Kristjan S Gudmundsson; Huiqiang Zhou; Ed W McLean; Jennifer P Peckham; Thimysta C Burnette; Harry Marr; Richard J Hazen; Lynn Condreay; Lance Johnson; Jan Balzarini
Application of phosphoramidate ProTide technology significantly improves antiviral potency of carbocyclic adenosine derivatives.
Journal of medicinal chemistry 2006;49(24):7215-26.
2006: John F Miller; C Webster Andrews; Michael Brieger; Eric S Furfine; Michael R Hale; Mary H Hanlon; Richard J Hazen; Istvan Kaldor; Ed W McLean; David Reynolds; Douglas M Sammond; Andrew Spaltenstein; Roger D Tung; Elizabeth M Turner; Robert X Xu; Ronald G Sherrill
Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385.
Bioorganic & medicinal chemistry letters 2006;16(7):1788-94.
2006: P J Yates; Richard J Hazen; Marty St Clair; Lawrence R Boone; Margaret Tisdale; Robert Elston
In vitro development of resistance to human immunodeficiency virus protease inhibitor GW640385.
Antimicrobial agents and chemotherapy 2006;50(3):1092-5.
2006: Karen R Romines; George A Freeman; Lee T Schaller; Jill R Cowan; Stephen S Gonzales; Jeffrey H Tidwell; C Webster Andrews; David K Stammers; Richard J Hazen; Robert G Ferris; Steven A Short; Joseph H Chan; Lawrence R Boone
Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor.
Journal of medicinal chemistry 2006;49(2):727-39.
2005: Richard J Hazen; Robert J Harvey; Marty St Clair; Robert G Ferris; George A Freeman; Jeffrey H Tidwell; Lee T Schaller; Jill R Cowan; Steven A Short; Karen R Romines; Joseph H Chan; Lawrence R Boone
Anti-human immunodeficiency virus type 1 activity of the nonnucleoside reverse transcriptase inhibitor GW678248 in combination with other antiretrovirals against clinical isolate viruses and in vitro selection for resistance.
Antimicrobial agents and chemotherapy 2005;49(11):4465-73.
2005: Robert G Ferris; Richard J Hazen; Grace B Roberts; Marty St Clair; Joseph H Chan; Karen R Romines; George A Freeman; Jeffrey H Tidwell; Lee T Schaller; Jill R Cowan; Steven A Short; Kurt L Weaver; Dean W Selleseth; Kelly R Moniri; Lawrence R Boone
Antiviral activity of GW678248, a novel benzophenone nonnucleoside reverse transcriptase inhibitor.
Antimicrobial agents and chemotherapy 2005;49(10):4046-51.
2005: E Randall Lanier; Richard J Hazen; Lisa Ross; Andy Freeman; Robert Harvey
Lack of antagonism between abacavir, lamivudine, and tenofovir against wild-type and drug-resistant HIV-1.
Journal of acquired immune deficiency syndromes (1999) 2005;39(5):519-22.
2005: John F Miller; Michael Brieger; Eric S Furfine; Richard J Hazen; Istvan Kaldor; David Reynolds; Ronald G Sherrill; Andrew Spaltenstein
Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles.
Bioorganic & medicinal chemistry letters 2005;15(15):3496-500.
2005: Ronald G Sherrill; Eric S Furfine; Richard J Hazen; John F Miller; David J Reynolds; Douglas M Sammond; Andrew Spaltenstein; Pat Wheelan; Lois L Wright
Synthesis and antiviral activities of novel N-alkoxy-arylsulfonamide-based HIV protease inhibitors.
Bioorganic & medicinal chemistry letters 2005;15(15):3560-4.
2005: Christopher McGuigan; Sarah A Harris; Susan M Daluge; Kristjan S Gudmundsson; Ed W McLean; Thimysta C Burnette; Harry Marr; Richard J Hazen; Lynn Condreay; Lance Johnson; Erik De Clercq; Jan Balzarini
Application of phosphoramidate pronucleotide technology to abacavir leads to a significant enhancement of antiviral potency.
Journal of medicinal chemistry 2005;48(10):3504-15.
2005: Ronald G Sherrill; C Webster Andrews; William J Bock; Ronda G Davis-Ward; Eric S Furfine; Richard J Hazen; Randy D Rutkowske; Andrew Spaltenstein; Lois L Wright
Optimization of pyrrolidinone based HIV protease inhibitors.
Bioorganic & medicinal chemistry letters 2005;15(1):81-4.
2004: George A Freeman; C Webster Andrews Iii; Andrew L Hopkins; Gina S Lowell; Lee T Schaller; Jill R Cowan; Stephen S Gonzales; George W Koszalka; Richard J Hazen; Lawrence R Boone; Robert G Ferris; Katrina L Creech; Grace B Roberts; Steven A Short; Kurt Weaver; David J Reynolds; John Milton; Jingshan Ren; David I Stuart; David K Stammers; Joseph H Chan
Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
Journal of medicinal chemistry 2004;47(24):5923-36.
2004: Andrew L Hopkins; Jingshan Ren; John Milton; Richard J Hazen; Joseph H Chan; David I Stuart; David K Stammers
Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.
Journal of medicinal chemistry 2004;47(24):5912-22.
2004: Joseph H Chan; George A Freeman; Jeffrey H Tidwell; Karen R Romines; Lee T Schaller; Jill R Cowan; Stephen S Gonzales; Gina S Lowell; C Webster Andrews; David J Reynolds; Marty St Clair; Richard J Hazen; Robert G Ferris; Katrina L Creech; Grace B Roberts; Steven A Short; Kurt Weaver; George W Koszalka; Lawrence R Boone
Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
Journal of medicinal chemistry 2004;47(5):1175-82.
2004: John F Miller; Eric S Furfine; Mary H Hanlon; Richard J Hazen; John A Ray; Laurence Robinson; Vicente Samano; Andrew Spaltenstein
Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains.
Bioorganic & medicinal chemistry letters 2004;14(4):959-63.
2004: Kristjan S Gudmundsson; Zhicheng Wang; Susan M Daluge; Lance C Johnson; Richard J Hazen; Lynn Condreay; Christopher McGuigan
Phosphoramidate protides of carbocyclic 2',3'-dideoxy-2',3'-didehydro-7-deazaadenosine with potent activity against HIV and HBV.
Nucleosides, nucleotides & nucleic acids 2004;23(12):1929-37.
2003: Kristjan S Gudmundsson; Susan M Daluge; Lance C Johnson; Robert Jansen; Richard J Hazen; Lynn Condreay; Christopher McGuigan
Phosphoramidate protides of 2',3'-dideoxy-3'-fluoroadenosine and related nucleosides with potent activity against HIV and HBV.
Nucleosides, nucleotides & nucleic acids 2003;22(10):1953-61.
2003: Richard J Hazen; E Randall Lanier
Relative anti-HIV-1 efficacy of lamivudine and emtricitabine in vitro is dependent on cell type.
Journal of acquired immune deficiency syndromes (1999) 2003;32(3):255-8.
2001: Joseph H Chan; J S Hong; R N Hunter ; Gloria Faye Orr; Jill R Cowan; D B Sherman; S M Sparks; B E Reitter; C Webster Andrews; Richard J Hazen; Marty St Clair; Lawrence R Boone; Robert G Ferris; Katrina L Creech; Grace B Roberts; Steven A Short; Kurt Weaver; R J Ott; Jingshan Ren; A Hopkins; David I Stuart; David K Stammers
2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
Journal of medicinal chemistry 2001;44(12):1866-82.
2000: Andrew Spaltenstein; Merrick R Almond; W J Bock; D G Cleary; Eric S Furfine; Richard J Hazen; Wieslaw M Kazmierski; FG Salituro; Roger D Tung; Lois L Wright
Novel inhibitors of HIV protease: design, synthesis and biological evaluation of picomolar inhibitors containing cyclic P1/P2 scaffolds.
Bioorganic & medicinal chemistry letters 2000;10(11):1159-62.